Study of EZN-2208 Pediatric Patients With Solid Tumors

Inclusion Criteria: * Patients with histologic verification of malignancy at original diagnosis or relapse. * Measurable or evaluable disease * Karnofsky score more or equal to 50 for patients \>16 years of age and Lansky score more or equal to 50 for patients \<16 years of age * Patients previously treated with irinotecan will be eligible for this study if they have not had documented progressive disease during treatment with an irinotecan-containing regimen. * Adequate hematologic, hepatic, coagulation, renal, and metabolic function Exclusion Criteria: * Pregnant or breast feeding patients will not be enrolled in this study * Patients who are currently receiving other anticancer agents * Patients who have an uncontrolled infection * Patients requiring cytochrome P450 3A4 enzyme inducing or inhibiting agents